Wilkins Investment Counsel Inc. Trims Stock Holdings in Illumina, Inc. $ILMN

Wilkins Investment Counsel Inc. reduced its stake in Illumina, Inc. (NASDAQ:ILMN) by 7.7% during the 4th quarter, Holdings Channel reports. The institutional investor owned 131,320 shares of the life sciences company’s stock after selling 10,915 shares during the period. Illumina comprises approximately 2.5% of Wilkins Investment Counsel Inc.’s investment portfolio, making the stock its 14th largest position. Wilkins Investment Counsel Inc.’s holdings in Illumina were worth $17,224,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Board of the Pension Protection Fund purchased a new stake in Illumina in the 4th quarter valued at about $26,000. Creative Capital Management Investments LLC raised its holdings in Illumina by 160.0% in the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after buying an additional 120 shares during the period. TD Waterhouse Canada Inc. purchased a new stake in Illumina in the 4th quarter valued at about $26,000. Laurel Wealth Advisors LLC purchased a new stake in Illumina in the 4th quarter valued at about $26,000. Finally, Quent Capital LLC purchased a new stake in Illumina in the 3rd quarter valued at about $29,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Price Performance

ILMN stock opened at $135.78 on Friday. The company has a market capitalization of $20.63 billion, a P/E ratio of 24.69, a PEG ratio of 2.60 and a beta of 1.42. Illumina, Inc. has a twelve month low of $73.86 and a twelve month high of $155.53. The business has a 50 day simple moving average of $125.68 and a 200-day simple moving average of $126.65. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.71% and a net margin of 19.42%.The business had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the prior year, the business earned $0.97 earnings per share. The company’s quarterly revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts anticipate that Illumina, Inc. will post 5.15 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on ILMN shares. JPMorgan Chase & Co. boosted their price target on shares of Illumina from $120.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday. Evercore reiterated an “outperform” rating on shares of Illumina in a research note on Friday. Robert W. Baird set a $137.00 price target on shares of Illumina in a research note on Friday, February 6th. Stifel Nicolaus boosted their price target on shares of Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Finally, Guggenheim boosted their price target on shares of Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Six analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $130.13.

Insider Transactions at Illumina

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the transaction, the senior vice president owned 16,321 shares in the company, valued at approximately $1,896,173.78. This represents a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 2.90% of the company’s stock.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q1 beat on both EPS and revenue, with non?GAAP EPS $1.15 vs. $1.05 consensus and revenue $1.09B (up 4.8% y/y); management raised FY?2026 EPS guidance to $5.15–$5.30 and updated revenue targets — this underpins the stock strength. Illumina Reports Financial Results for First Quarter of Fiscal Year 2026
• Positive Sentiment: Management cited surging NovaSeq X demand and growth in clinical sequencing as a primary driver of revenue momentum — a product?driven acceleration that supports durable top?line growth. ILMN Q1 deep dive: Clinical sequencing fuels growth as NovaSeq X demand surges
• Positive Sentiment: Board authorized an additional $1.5B in share repurchases, expanding buybacks alongside better margins — a capital?return boost that can support near?term EPS and investor sentiment. Illumina lifts 2026 outlook and expands share buybacks
• Neutral Sentiment: Analysts are updating models: JPMorgan raised its price target to $125 but kept a “neutral” rating, reflecting mixed views on near?term upside despite operational improvements. Analyst Price Target Update
• Negative Sentiment: Even with the PT bump, the $125 target implies a mid?single?digit to low?double?digit downside from current levels — a reminder that some analysts still see limited valuation upside and room for multiple compression. Analyst Price Target Update

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.